Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8871035 | 0.81 | CES2 (0.55) | CES2CES1ALDH1A1MEN1HTT | |
| SCHEMBL9448908 | 0.79 | ALDH1A1 (0.61) | CES2CES1ALDH1A1MEN1HTT | |
| SCHEMBL9448883 | 0.75 | ALDH1A1 (0.52) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL9449036 | 0.75 | ALDH1A1 (0.47) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL2327686 | 0.73 | CES2 (0.56) | CES2CES1ALDH1A1HCAR1SLC6A3 | |
| SCHEMBL5471366 | 0.71 | CES2 (0.54) | CES2CES1ALDH1A1MEN1KMT2A | |
| Water SCHEMBL8938130 | 0.71 | CES2 (0.54) | CES2CES1ALDH1A1HCAR1SLC6A3 | |
| SCHEMBL30345150 | 0.71 | ALDH1A1 (0.47) | ALDH1A1MEN1HTTKMT2AHIF1A | |
| SCHEMBL6116830 | 0.71 | ALDH1A1 (0.47) | CES2CES1ALDH1A1MEN1HTT | |
| SCHEMBL9449106 | 0.71 | ABCG2 (0.53) | CES2CES1ALDH1A1MEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-08 | — | — | US | disclosed |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-08 | — | — | US | disclosed |
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| EP-1789404-A2 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060040936-A1 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION | 2006-02-23 | — | — | US | disclosed |
| WO-2006004880-A2 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2006-01-12 | — | — | WO | disclosed |
| EP-0466730-B1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1993-07-21 | — | — | EP | disclosed |
| US-5220021-A | Geminal bisphosphonic acids and derivatives as anti-arthritic agents | THE UPJOHN COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| EP-0466730-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS. | UPJOHN CO (US) | 1992-01-22 | — | — | EP | disclosed |
| WO-1990012017-A1 | GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS | THE UPJOHN COMPANY (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | CES2 1004/4885CES1 229/4885ALDH1A1 3632/4885 |
| US-20100087425-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | CES2 1041/4885CES1 267/4885ALDH1A1 3682/4885 |
| US-20060040936-A1 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | BACE1, BACE2, APP | CES2 1004/4885CES1 229/4885ALDH1A1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.